 Kurtis Davies
Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 13 | 2024 | 961 | 2.700 |
Why?
| | Lung Neoplasms | 16 | 2024 | 2177 | 2.620 |
Why?
| | Oncogene Proteins, Fusion | 10 | 2021 | 179 | 2.180 |
Why?
| | Proto-Oncogene Proteins | 11 | 2024 | 608 | 2.060 |
Why?
| | Protein-Tyrosine Kinases | 8 | 2024 | 395 | 1.990 |
Why?
| | High-Throughput Nucleotide Sequencing | 8 | 2023 | 439 | 1.890 |
Why?
| | Mutation | 11 | 2024 | 3346 | 1.660 |
Why?
| | Pathology, Molecular | 2 | 2021 | 26 | 1.400 |
Why?
| | Proto-Oncogene Proteins c-met | 2 | 2021 | 67 | 1.330 |
Why?
| | Protein Kinase Inhibitors | 12 | 2024 | 785 | 1.220 |
Why?
| | Exons | 4 | 2022 | 302 | 1.180 |
Why?
| | Biomarkers, Tumor | 11 | 2023 | 1040 | 1.170 |
Why?
| | ErbB Receptors | 6 | 2024 | 554 | 1.060 |
Why?
| | Endometrial Neoplasms | 2 | 2023 | 141 | 0.920 |
Why?
| | Neoplasms | 6 | 2023 | 2097 | 0.900 |
Why?
| | Drug Resistance, Neoplasm | 7 | 2024 | 638 | 0.840 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 126 | 0.830 |
Why?
| | Pyrazoles | 4 | 2013 | 362 | 0.830 |
Why?
| | Oncogene Fusion | 2 | 2019 | 9 | 0.770 |
Why?
| | Protein Kinases | 3 | 2017 | 307 | 0.770 |
Why?
| | Brain Neoplasms | 7 | 2021 | 979 | 0.670 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2018 | 309 | 0.650 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 5 | 0.650 |
Why?
| | Immunohistochemistry | 1 | 2023 | 1629 | 0.650 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2019 | 46 | 0.630 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2020 | 228 | 0.630 |
Why?
| | Gene Fusion | 1 | 2018 | 18 | 0.610 |
Why?
| | DNA, Neoplasm | 1 | 2019 | 157 | 0.610 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2019 | 92 | 0.610 |
Why?
| | Receptor Protein-Tyrosine Kinases | 5 | 2019 | 226 | 0.580 |
Why?
| | Antineoplastic Agents | 5 | 2018 | 1879 | 0.550 |
Why?
| | Laboratory Proficiency Testing | 1 | 2016 | 7 | 0.530 |
Why?
| | Pyridines | 3 | 2013 | 425 | 0.500 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2015 | 60 | 0.480 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2019 | 859 | 0.460 |
Why?
| | Genetic Testing | 1 | 2016 | 381 | 0.430 |
Why?
| | Computational Biology | 2 | 2018 | 530 | 0.430 |
Why?
| | Glioma | 3 | 2021 | 294 | 0.420 |
Why?
| | RNA | 1 | 2019 | 809 | 0.420 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type IIb | 1 | 2012 | 9 | 0.410 |
Why?
| | Neurons | 4 | 2012 | 1280 | 0.410 |
Why?
| | Humans | 42 | 2024 | 114705 | 0.410 |
Why?
| | Cell Line, Tumor | 12 | 2024 | 2711 | 0.390 |
Why?
| | Cell Proliferation | 8 | 2018 | 2187 | 0.370 |
Why?
| | Hippocampus | 4 | 2008 | 693 | 0.350 |
Why?
| | beta Catenin | 2 | 2023 | 219 | 0.330 |
Why?
| | Synaptic Membranes | 1 | 2008 | 18 | 0.310 |
Why?
| | Pyrimidines | 1 | 2011 | 376 | 0.310 |
Why?
| | Subcellular Fractions | 2 | 2008 | 78 | 0.300 |
Why?
| | Long-Term Synaptic Depression | 1 | 2008 | 48 | 0.300 |
Why?
| | Glioblastoma | 2 | 2021 | 253 | 0.300 |
Why?
| | Cell Cycle Proteins | 1 | 2011 | 551 | 0.290 |
Why?
| | Receptors, AMPA | 1 | 2008 | 119 | 0.290 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 1356 | 0.290 |
Why?
| | Nuclear Proteins | 1 | 2011 | 591 | 0.280 |
Why?
| | DNA Mutational Analysis | 3 | 2023 | 372 | 0.280 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2007 | 172 | 0.270 |
Why?
| | Molecular Targeted Therapy | 4 | 2018 | 347 | 0.270 |
Why?
| | Signal Transduction | 7 | 2018 | 4516 | 0.260 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 2 | 2023 | 31 | 0.260 |
Why?
| | DNA Polymerase II | 2 | 2023 | 37 | 0.260 |
Why?
| | Gene Rearrangement | 2 | 2019 | 135 | 0.260 |
Why?
| | Phosphorylation | 7 | 2015 | 1569 | 0.250 |
Why?
| | Female | 22 | 2023 | 59521 | 0.250 |
Why?
| | c-Mer Tyrosine Kinase | 4 | 2018 | 43 | 0.240 |
Why?
| | Prognosis | 6 | 2023 | 3330 | 0.240 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2017 | 192 | 0.240 |
Why?
| | Colorectal Neoplasms | 2 | 2022 | 615 | 0.240 |
Why?
| | Male | 22 | 2021 | 55607 | 0.220 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 37 | 0.220 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2023 | 445 | 0.200 |
Why?
| | raf Kinases | 1 | 2021 | 11 | 0.200 |
Why?
| | Drug Synergism | 4 | 2018 | 317 | 0.190 |
Why?
| | Checkpoint Kinase 1 | 2 | 2011 | 28 | 0.190 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2021 | 12 | 0.190 |
Why?
| | Receptor, ErbB-2 | 2 | 2022 | 300 | 0.190 |
Why?
| | DNA Copy Number Variations | 2 | 2019 | 154 | 0.180 |
Why?
| | Aged | 10 | 2023 | 19074 | 0.180 |
Why?
| | GTP Phosphohydrolases | 1 | 2020 | 65 | 0.170 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 276 | 0.170 |
Why?
| | Middle Aged | 11 | 2023 | 26738 | 0.170 |
Why?
| | Microtubule-Associated Proteins | 1 | 2021 | 174 | 0.170 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 17 | 0.170 |
Why?
| | Cell Cycle | 2 | 2012 | 542 | 0.160 |
Why?
| | Aged, 80 and over | 4 | 2023 | 6347 | 0.160 |
Why?
| | Carcinoma, Endometrioid | 1 | 2019 | 46 | 0.160 |
Why?
| | Carcinogenesis | 1 | 2020 | 177 | 0.150 |
Why?
| | Gene Amplification | 2 | 2019 | 95 | 0.150 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2018 | 26 | 0.150 |
Why?
| | Ependymoma | 1 | 2019 | 155 | 0.150 |
Why?
| | Smokers | 1 | 2018 | 129 | 0.140 |
Why?
| | Membrane Proteins | 2 | 2020 | 1019 | 0.140 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 124 | 0.140 |
Why?
| | Neoplasm Staging | 3 | 2019 | 1167 | 0.140 |
Why?
| | Chloroquine | 1 | 2017 | 52 | 0.140 |
Why?
| | Rats, Sprague-Dawley | 4 | 2012 | 2218 | 0.140 |
Why?
| | Ganglioglioma | 1 | 2016 | 31 | 0.130 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 79 | 0.130 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2017 | 699 | 0.130 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 2 | 2013 | 33 | 0.130 |
Why?
| | Astrocytoma | 1 | 2016 | 108 | 0.130 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2016 | 34 | 0.130 |
Why?
| | Adult | 8 | 2023 | 30553 | 0.130 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 2 | 2007 | 156 | 0.120 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 111 | 0.120 |
Why?
| | Laboratories | 1 | 2016 | 95 | 0.120 |
Why?
| | Biomarkers | 2 | 2024 | 3408 | 0.120 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 386 | 0.120 |
Why?
| | Oncogenes | 1 | 2015 | 103 | 0.120 |
Why?
| | Genetic Variation | 1 | 2019 | 870 | 0.120 |
Why?
| | Rats | 5 | 2012 | 4958 | 0.120 |
Why?
| | Mutation, Missense | 1 | 2016 | 293 | 0.120 |
Why?
| | Indoles | 1 | 2017 | 304 | 0.120 |
Why?
| | Autophagy | 1 | 2017 | 235 | 0.120 |
Why?
| | Melanoma | 1 | 2020 | 620 | 0.120 |
Why?
| | Cell Survival | 2 | 2017 | 1021 | 0.120 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2013 | 352 | 0.110 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2016 | 194 | 0.110 |
Why?
| | Health Care Surveys | 1 | 2016 | 539 | 0.110 |
Why?
| | Head and Neck Neoplasms | 1 | 2018 | 427 | 0.110 |
Why?
| | Receptor, trkA | 1 | 2013 | 16 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2016 | 1143 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2020 | 756 | 0.110 |
Why?
| | Sulfonamides | 1 | 2017 | 445 | 0.110 |
Why?
| | Genomics | 1 | 2018 | 635 | 0.110 |
Why?
| | RNA, Small Interfering | 2 | 2014 | 535 | 0.110 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 161 | 0.110 |
Why?
| | Thyroid Neoplasms | 1 | 2016 | 264 | 0.100 |
Why?
| | Syndecan-4 | 1 | 2012 | 7 | 0.100 |
Why?
| | Prospective Studies | 1 | 2023 | 6220 | 0.100 |
Why?
| | Databases, Factual | 1 | 2016 | 1125 | 0.100 |
Why?
| | Animals | 9 | 2018 | 31709 | 0.090 |
Why?
| | Pyrimidinones | 1 | 2011 | 88 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2022 | 1862 | 0.090 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 2 | 2012 | 180 | 0.090 |
Why?
| | DNA Replication | 1 | 2011 | 202 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 4624 | 0.090 |
Why?
| | HeLa Cells | 1 | 2011 | 562 | 0.090 |
Why?
| | Apoptosis | 3 | 2015 | 2363 | 0.080 |
Why?
| | Protein Transport | 2 | 2008 | 395 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2020 | 242 | 0.080 |
Why?
| | Microdissection | 1 | 2008 | 15 | 0.080 |
Why?
| | In Vitro Techniques | 2 | 2008 | 1016 | 0.080 |
Why?
| | Cohort Studies | 1 | 2018 | 4895 | 0.080 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 1264 | 0.080 |
Why?
| | Carboplatin | 2 | 2020 | 135 | 0.070 |
Why?
| | Threonine | 1 | 2007 | 40 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2020 | 4411 | 0.070 |
Why?
| | Neuronal Plasticity | 1 | 2008 | 209 | 0.070 |
Why?
| | Infant | 4 | 2020 | 7964 | 0.070 |
Why?
| | Mice, Nude | 2 | 2018 | 630 | 0.070 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1121 | 0.060 |
Why?
| | Survival Rate | 2 | 2020 | 1644 | 0.060 |
Why?
| | Synapses | 1 | 2008 | 331 | 0.060 |
Why?
| | Biological Products | 1 | 2007 | 166 | 0.060 |
Why?
| | Piperazines | 2 | 2018 | 309 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 523 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2007 | 1226 | 0.060 |
Why?
| | Ischemia | 1 | 2007 | 362 | 0.060 |
Why?
| | Mice | 3 | 2017 | 14872 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2020 | 12556 | 0.050 |
Why?
| | Vinblastine | 1 | 2020 | 63 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 62 | 0.040 |
Why?
| | Protein Tyrosine Phosphatases | 2 | 2012 | 147 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2020 | 5047 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 32 | 0.040 |
Why?
| | Models, Molecular | 2 | 2018 | 1369 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 76 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 30 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2007 | 2320 | 0.040 |
Why?
| | Phthalazines | 1 | 2018 | 38 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 140 | 0.040 |
Why?
| | Cetuximab | 1 | 2018 | 90 | 0.040 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2017 | 21 | 0.040 |
Why?
| | Child | 3 | 2021 | 18420 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2017 | 25 | 0.040 |
Why?
| | Quality Control | 1 | 2017 | 144 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 502 | 0.030 |
Why?
| | Workflow | 1 | 2017 | 133 | 0.030 |
Why?
| | Child, Preschool | 2 | 2020 | 9118 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2013 | 2785 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2017 | 187 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 262 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 84 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 923 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2014 | 33 | 0.030 |
Why?
| | Oncogene Protein v-akt | 1 | 2014 | 26 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 591 | 0.030 |
Why?
| | STAT6 Transcription Factor | 1 | 2014 | 22 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 442 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2019 | 577 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 723 | 0.030 |
Why?
| | Phosphatidylserines | 1 | 2014 | 87 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2014 | 94 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2014 | 146 | 0.030 |
Why?
| | Drug Resistance | 1 | 2014 | 158 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2018 | 9088 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2014 | 164 | 0.030 |
Why?
| | Adenine | 1 | 2015 | 219 | 0.030 |
Why?
| | Adolescent | 2 | 2021 | 17853 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1694 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 281 | 0.030 |
Why?
| | Transcriptome | 1 | 2018 | 726 | 0.030 |
Why?
| | Memantine | 1 | 2012 | 16 | 0.030 |
Why?
| | N-Methylaspartate | 1 | 2012 | 37 | 0.030 |
Why?
| | Down-Regulation | 1 | 2014 | 594 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3003 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 329 | 0.020 |
Why?
| | Receptors, GABA-A | 1 | 2012 | 82 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 235 | 0.020 |
Why?
| | Biological Transport | 1 | 2012 | 374 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 1842 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2016 | 688 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1518 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 367 | 0.020 |
Why?
| | Long-Term Potentiation | 1 | 2012 | 145 | 0.020 |
Why?
| | Synaptic Transmission | 1 | 2012 | 227 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2012 | 785 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2017 | 2765 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 1880 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 6116 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2014 | 720 | 0.020 |
Why?
| | Phenanthrolines | 1 | 2008 | 7 | 0.020 |
Why?
| | Bicuculline | 1 | 2008 | 21 | 0.020 |
Why?
| | GABA Antagonists | 1 | 2008 | 32 | 0.020 |
Why?
| | Biophysical Phenomena | 1 | 2008 | 63 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2008 | 151 | 0.020 |
Why?
| | Quinoxalines | 1 | 2008 | 60 | 0.020 |
Why?
| | Excitatory Postsynaptic Potentials | 1 | 2008 | 98 | 0.020 |
Why?
| | Patch-Clamp Techniques | 1 | 2008 | 239 | 0.020 |
Why?
| | Tyrosine | 1 | 2008 | 214 | 0.020 |
Why?
| | Spodoptera | 1 | 2007 | 36 | 0.020 |
Why?
| | Organometallic Compounds | 1 | 2008 | 98 | 0.020 |
Why?
| | Protein Subunits | 1 | 2008 | 201 | 0.020 |
Why?
| | Glutamic Acid | 1 | 2008 | 211 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2007 | 352 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2007 | 368 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2015 | 3535 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2007 | 796 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2007 | 1982 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 10471 | 0.010 |
Why?
| | Peptides | 1 | 2007 | 848 | 0.010 |
Why?
| | Protein Binding | 1 | 2007 | 1890 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2637 | 0.010 |
Why?
| | Islets of Langerhans | 1 | 2007 | 726 | 0.010 |
Why?
| | Insulin | 1 | 2007 | 2080 | 0.010 |
Why?
|
|
Davies's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|